Phenotypes associated with this allele

• Allele Symbol: Tg(MMTV-KRAS*G12V)3025Mrl
• Allele Name: transgene insertion 3025, Merck Research Laboratory
• Allele ID: MGI:5827748
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(MMTV-KRAS*G12V)3025Mrl/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0	involves: C57BL/6 * FVB/N * SJL	MGI:5827761
tg2	Tg(MMTV-KRAS*G12V)3025Mrl/0	involves: C57BL/6 * FVB * SJL	MGI:5827750

Genotype
MGI:5827761

cx1

• Allelic Composition: Tg(MMTV-KRAS*G12V)3025Mrl/0; Tg(MMTV-rtTA)1Lach/0; Tg(tetO-MYC)1Lach/0
• Genetic Background: involves: C57BL/6 * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

integument

increased mammary gland tumor incidence ( J:133578 )

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:133578

Genotype
MGI:5827750

tg2

• Allelic Composition: Tg(MMTV-KRAS*G12V)3025Mrl/0
• Genetic Background: involves: C57BL/6 * FVB * SJL

vision/eye

retina degeneration ( J:77272 )

• moderate retinal atrophy characterized by loss of the outer layers (rods and cones, outer nuclear layer, and outer plexiform layer)

neoplasm

increased mammary adenocarcinoma incidence ( J:77272 )

• males and females develop mammary tumors

• tumor latency is inversely correlated with generation number, with tumor latency for F1 females being 8 months and 5 months for F3 females

• mice develop multiple, distinct tumors, with an average tumor burden of 5 tumors per mouse

• tumors are adenocarcinomas

• treatment with the FPTase inhibitor L-744,832 results in inhibition of tumor growth

increased metastatic potential ( J:77272 )

• metastases to the lung are occasionally seen

integument

increased mammary adenocarcinoma incidence ( J:77272 )

• males and females develop mammary tumors

• tumor latency is inversely correlated with generation number, with tumor latency for F1 females being 8 months and 5 months for F3 females

• mice develop multiple, distinct tumors, with an average tumor burden of 5 tumors per mouse

• tumors are adenocarcinomas

• treatment with the FPTase inhibitor L-744,832 results in inhibition of tumor growth

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:77272 )

• males and females develop mammary tumors

• tumor latency is inversely correlated with generation number, with tumor latency for F1 females being 8 months and 5 months for F3 females

• mice develop multiple, distinct tumors, with an average tumor burden of 5 tumors per mouse

• tumors are adenocarcinomas

• treatment with the FPTase inhibitor L-744,832 results in inhibition of tumor growth